Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free MRV Stock Alerts

Nuvo Pharmaceuticals (MRV) Competitors

C$49.20 +1.69 (+3.56%)
As of 02:35 PM Eastern
Compare

MRV vs. VRX, APHA, BHC, CRON, and THCX

Should you buy Nuvo Pharmaceuticals stock or one of its competitors? MarketBeat compares Nuvo Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvo Pharmaceuticals include Valeant Pharmaceuticals International (VRX), Aphria (APHA), Bausch Health Companies (BHC), Cronos Group (CRON), and Hydropothecary (THCX). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Nuvo Pharmaceuticals compare to Valeant Pharmaceuticals International?

Nuvo Pharmaceuticals (TSE:MRV) and Valeant Pharmaceuticals International (TSE:VRX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Valeant Pharmaceuticals International's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Valeant Pharmaceuticals International's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvo Pharmaceuticals20.95% 1,180.47% 5.85%
Valeant Pharmaceuticals International N/A N/A N/A

In the previous week, Nuvo Pharmaceuticals' average media sentiment score of 0.00 equaled Valeant Pharmaceuticals International'saverage media sentiment score.

Company Overall Sentiment
Nuvo Pharmaceuticals Neutral
Valeant Pharmaceuticals International Neutral

Nuvo Pharmaceuticals has higher revenue and earnings than Valeant Pharmaceuticals International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo PharmaceuticalsC$8.72B5.01C$15.17MC$2.9117.17
Valeant Pharmaceuticals InternationalN/AN/AN/AN/AN/A

1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Nuvo Pharmaceuticals beats Valeant Pharmaceuticals International on 6 of the 6 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Aphria?

Aphria (TSE:APHA) and Nuvo Pharmaceuticals (TSE:MRV) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Aphria's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Aphria's return on equity.

Company Net Margins Return on Equity Return on Assets
AphriaN/A N/A N/A
Nuvo Pharmaceuticals 20.95%1,180.47%5.85%

In the previous week, Aphria's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Aphria Neutral
Nuvo Pharmaceuticals Neutral

Nuvo Pharmaceuticals has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AphriaC$611.06M0.00-C$637.39M-C$2.01N/A
Nuvo PharmaceuticalsC$8.72B5.01C$15.17MC$2.9117.17

Summary

Nuvo Pharmaceuticals beats Aphria on 9 of the 9 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Bausch Health Companies?

Nuvo Pharmaceuticals (TSE:MRV) and Bausch Health Companies (TSE:BHC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Nuvo Pharmaceuticals has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo PharmaceuticalsC$8.72B5.01C$15.17MC$2.9117.17
Bausch Health CompaniesC$10.53B0.25-C$125.65M-C$3.24N/A

1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. Comparatively, 10.0% of Bausch Health Companies shares are held by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are held by insiders. Comparatively, 11.3% of Bausch Health Companies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Bausch Health Companies' net margin of -13.54%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Bausch Health Companies' return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvo Pharmaceuticals20.95% 1,180.47% 5.85%
Bausch Health Companies -13.54%120.43%4.16%

In the previous week, Nuvo Pharmaceuticals' average media sentiment score of 0.00 equaled Bausch Health Companies'average media sentiment score.

Company Overall Sentiment
Nuvo Pharmaceuticals Neutral
Bausch Health Companies Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvo Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Bausch Health Companies
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Nuvo Pharmaceuticals has a beta of 0.917796, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Bausch Health Companies has a beta of 0.631102, suggesting that its stock price is 37% less volatile than the broader market.

Summary

Nuvo Pharmaceuticals beats Bausch Health Companies on 8 of the 12 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Cronos Group?

Nuvo Pharmaceuticals (TSE:MRV) and Cronos Group (TSE:CRON) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Nuvo Pharmaceuticals has higher revenue and earnings than Cronos Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo PharmaceuticalsC$8.72B5.01C$15.17MC$2.9117.17
Cronos GroupC$159.54M8.83-C$32.78MN/AN/A

Cronos Group has a consensus target price of C$4.75, indicating a potential upside of 25.99%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts plainly believe Cronos Group is more favorable than Nuvo Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvo Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Cronos Group's net margin of -1.29%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvo Pharmaceuticals20.95% 1,180.47% 5.85%
Cronos Group -1.29%-0.19%-3.73%

In the previous week, Nuvo Pharmaceuticals' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company Overall Sentiment
Nuvo Pharmaceuticals Neutral
Cronos Group Neutral

1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.4% of Cronos Group shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by company insiders. Comparatively, 46.4% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nuvo Pharmaceuticals has a beta of 0.917796, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Cronos Group has a beta of 1.11805, suggesting that its stock price is 12% more volatile than the broader market.

Summary

Cronos Group beats Nuvo Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Hydropothecary?

Hydropothecary (CVE:THCX) and Nuvo Pharmaceuticals (TSE:MRV) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nuvo Pharmaceuticals has higher revenue and earnings than Hydropothecary.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HydropothecaryN/AN/AN/AN/AN/A
Nuvo PharmaceuticalsC$8.72B5.01C$15.17MC$2.9117.17

In the previous week, Hydropothecary's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Hydropothecary Neutral
Nuvo Pharmaceuticals Neutral

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Hydropothecary's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Hydropothecary's return on equity.

Company Net Margins Return on Equity Return on Assets
HydropothecaryN/A N/A N/A
Nuvo Pharmaceuticals 20.95%1,180.47%5.85%

Summary

Nuvo Pharmaceuticals beats Hydropothecary on 6 of the 6 factors compared between the two stocks.

Get Nuvo Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRV vs. The Competition

Export
MetricNuvo PharmaceuticalsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$43.71BC$2.44BC$6.26BC$12.13B
Dividend YieldN/A2.95%2.69%6.20%
P/E Ratio17.175.2122.4237.79
Price / Sales5.011,776.68548.0111.31
Price / Cash0.2310.1842.3182.29
Price / Book66.6110.909.824.60
Net IncomeC$15.17MC$20.70BC$3.56BC$299.09M
7 Day Performance53.91%-0.36%-1.17%0.76%
1 Month PerformanceN/A3.96%3.71%1.66%
1 Year PerformanceN/A16.18%27.28%51.70%

Nuvo Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRV
Nuvo Pharmaceuticals
N/AC$49.20
+3.6%		N/AN/AC$43.04BC$8.72B16.91N/A
VRX
Valeant Pharmaceuticals International
N/AN/AN/AN/AC$10.76BN/AN/AN/A
APHA
Aphria
N/AN/AN/AN/AC$5.24BC$611.06MN/A1,200
BHC
Bausch Health Companies
0.3443 of 5 stars		C$7.48
+0.4%		N/A+13.3%C$2.79BC$10.53BN/A19,900
CRON
Cronos Group
2.0082 of 5 stars		C$3.91
+4.3%		C$4.75
+21.5%		+43.9%C$1.46BC$159.54MN/A450

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MRV) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel